Latest News

Common multiple sclerosis drugs taken together do not reduce relapse risk

A recent clinical trial found that interferonβ-1a (INF) and glatiramer acetate (GA), two of the most commonly prescribed drugs for multiple sclerosis (MS), provide no additional clinical benefit when taken together. While findings suggest that taking both INF and GA together was not superior to GA monotherapy in reducing relapse risk; the combination therapy does appear to reduce new lesion activity and total lesion volume.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • A bad buzz: Men with HIV need fewer drinks to feel effects

  • Listen to your heart: Why your brain may give away how well you know yourself

  • Mindfulness-based therapy could offer an alternative to antidepressants for preventing depression relapse

  • New guideline advises when to treat a first seizure

  • Extending natalizumab up to 8 weeks shown safe and effective in patients with multiple sclerosis, report says

  • PTSD common in ICU Survivors

  • Frequent indoor tanning among teens shows correlation with smoking, social media use

  • Autism-epilepsy connection explored in four studies

  • Video games in care homes: connecting older adults, or exposing age-related vulnerability?

  • Reducing global tobacco use

  •